| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Cambinol (formerly NSC-112546) is a potent SIRT (silent information regulator enzymes) inhibitor with IC50 values of 56 and 59 μM for SIRT1 and SIRT2, respectively. It inhibits NAD-dependent deacetylase activity of human SIRT1 and SIRT2. Inhibition of SIRT1 activity with cambinol during genotoxic stress leads to hyperacetylation of key stress response proteins and promotes cell cycle arrest. Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induced apoptosis, which was accompanied by hyperacetylation of BCL6 and p53. Because acetylation inactivates BCL6 and has the opposite effect on the function of p53 and other checkpoint pathways, the antitumor activity of cambinol in Burkitt lymphoma cells may be accomplished through a combined effect of BCL6 inactivation and checkpoint activation. Cambinol was well tolerated in mice and inhibited growth of Burkitt lymphoma xenografts.
| ln Vitro |
Human SIRT1 and SIRT2 NAD-dependent deacetylase activity is inhibited by cambinol. Using Cambinol to inhibit SIRT1 activity during genotoxic stress causes important stress response proteins to become hyperacetylated, which in turn encourages cell cycle arrest. When cambinol is used alone to treat BCL6-expressing Burkitt lymphoma cells, it causes apoptosis along with hyperacetylation of p53 and BCL6. Cambinol exhibits no action against SIRT3 and only modest inhibition of SIRT5 (42% inhibition at 300 μM) [1].
|
||
|---|---|---|---|
| ln Vivo |
In mice, camebinol (100 mg/kg) is well tolerated and suppresses the growth of xenografts with Burkitt lymphoma. Animals treated with cambinol do not significantly lose weight in comparison to controls. Novel anticancer drugs could be NAD-dependent deacetylase inhibitors[1].
|
||
| Animal Protocol |
|
||
| References |
[1]. Heltweg B, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006 Apr 15;66(8):4368-77.
[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330 |
| Molecular Formula |
C21H16N2O2S
|
|
|---|---|---|
| Molecular Weight |
360.43
|
|
| CAS # |
14513-15-6
|
|
| Related CAS # |
|
|
| SMILES |
O=C(C(CC1=C2C=CC=CC2=CC=C1O)=C(C3=CC=CC=C3)N4)NC4=S
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7745 mL | 13.8723 mL | 27.7446 mL | |
| 5 mM | 0.5549 mL | 2.7745 mL | 5.5489 mL | |
| 10 mM | 0.2774 mL | 1.3872 mL | 2.7745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Sirtuin inhibitors.A,structure of splitomicin, cambinol (NSC-112546), and ADS012.B,cambinol inhibits human SIRT1 (IC50, 56 ± 2 μmol/L) and SIRT2 (IC50, 59 ± 4) NAD-dependent deacetylation of acetyl-histone H4 peptide.Cancer Res.2006 Apr 15;66(8):4368-77. |
|---|
Cambinol induces hyperacetylation of SIRT1 and SIRT2 substrates p53 and tubulin.Cancer Res.2006 Apr 15;66(8):4368-77. |
Inhibition of SIRT1 with cambinol sensitizes NCI H460 lung cancer cells to etoposide and paclitaxel and enhances etoposide-induced G2arrest.Cancer Res.2006 Apr 15;66(8):4368-77. |
Cambinol sensitizes cells to chemotherapeutic agents in a p53-independent manner.Cancer Res.2006 Apr 15;66(8):4368-77. |
|---|
Cambinol is active as a single agent in Burkitt lymphoma cell lines.Cancer Res.2006 Apr 15;66(8):4368-77. |
Cambinol induces hyperacetylation of p53 and BCL6 and interferes with BCL6 transcriptional repression.Cancer Res.2006 Apr 15;66(8):4368-77. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
